PRACTICAL ONCOLOGY JOURNAL ›› 2010, Vol. 24 ›› Issue (1): 41-44.doi: 10.3969/j.issn.1002-3070.2010.01.010

Previous Articles     Next Articles

Therapeutic evaluation of 125I radioactive seeds through interstitial brachytherapy for different malignant tumors

YU Hongbo, CUI Yali, LI Yanping, Wang Xinghua   

  1. Department of Nuclear Medichine,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081
  • Received:2010-01-05 Online:2010-02-28 Published:2015-01-23

Abstract: Objective To evalue recent efficiency and side effects of 125I seed brachytherapy for late-staged malignant tumors.Methods All the patients with residual or recurrent unresectable malignancies were treated with 125I seed implantation under CT scan after they were given a local anesthesia.The seeds were retrogradely placed with a gun applicator according to the previous therapy planning.Results All the patients were implanted succeedly and no severe complications were recorded postoperatively.In all cases,the particles didn′t fall off or shift.Only minority of patients showed light loss of thrombocyte and hemoglobin.Acute leucocytopenia was seen in 3 patients.A complete response was achieved in 5 patients and a partial response in 11 patients.6 patients were assessed as having stable disease while 1 patients having progressive disease.In three patients the serum TSGF level was increased significantly,which was supposed to be failure.The local control rate was 82.6%(19/23)and the total response rate was 69.6%(16/23).Thirty patients suffered the pain before treated with125I.Postoperatively a complete pain relief was achieved in 17 patients,a partial relief in 9 patients and no change in 4 patients.The response rate was 86.7%(26/30).The survival rate of 1,3,6 month and 1 year were 100%,94.59%,81.08% and 62.16% respectively.Conclusions 125I brachytherapy for late-staged malignant tumors gives a wide range,definite recent efficiency and satisfactory reliability.However,own to all the patients are very late-staged,a high survival rate have not been obtained.

Key words: 125I seed, Brachytherapy implantation, Late-staged malignant tumors

CLC Number: